When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
This proprietary rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock’s price performance over the trailing 52 weeks matches up against other publicly traded companies.
History reveals that the top-performing stocks typically have an RS Rating north of 80 in the early stages of their moves.
Is Cel-Sci Stock A Buy?
Cel-Sci stock has moved more than 5% past an 18.10 entry in a third-stage consolidation, meaning it’s now out of a proper buy range. Look for Cel-Sci stock to offer a new buying opportunity like a three-weeks-tight pattern or a pullback to the 50-day or 10-week line.
The maker of immunotherapy products reported a 12% earnings contraction in its most recent report. Revenue shrank by 100%.
Cel-Sci stock earns the No. 155 rank among its peers in the Medical-Biomed/Biotech industry group. Alexion Pharmaceuticals (ALXN) and Maravai Lifesciences (MRVI) are also among the group’s highest-rated stocks.
YOU MIGHT ALSO LIKE: